Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
RATIONALE: Abnormal oscillatory activity associated with N-methyl-D-aspartate (NMDA) receptor hypofunction is widely considered to contribute to the symptoms of schizophrenia. OBJECTIVE: This study aims to characterise the changes produced by NMDA receptor antagonists and antipsychotics on accumbal high-frequency oscillations (HFO; 130-180 Hz) in mice. METHODS: Local field potentials were recorded from the nucleus accumbens of freely moving mice. RESULTS: Systemic injection of ketamine and MK801 both dose-dependently increased the power of HFO and produced small increases in HFO frequency. The atypical antipsychotic drug, clozapine, produced a robust dose-dependent reduction in the frequency of MK801-enhanced HFO, whilst haloperidol, a typical antipsychotic drug, had little effect. Stimulation of NMDA receptors (directly or through the glycine site) as well as activation of 5-HT1A receptors, reduced the frequency of MK801-enhanced HFO, but other receptors known to be targets for clozapine, namely 5-HT2A, 5-HT7 and histamine H3 receptors had no effect. CONCLUSIONS: NMDA receptor antagonists and antipsychotics produce broadly similar fundamental effects on HFO, as reported previously for rats, but we did observe several notable differences. In mice, HFO at baseline were weak or not detectable unlike rats. Post-injection of NMDA receptor antagonists HFO was also weaker but significantly faster. Additionally, we found that atypical antipsychotic drugs may reduce the frequency of HFO by interacting with NMDA and/or 5-HT1A receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Like the effects of ketamine in the cortex, ketamine increases the power of high-frequency oscillations of local field potentials in the NAc in unanesthetized mice [242], suggesting a potential role for activity-dependent synapse strengthening mechanisms.”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [242]
The cited source says what the claim attributes to it.
In the citing paper
“Like the effects of ketamine in the cortex, ketamine increases the power of high-frequency oscillations of local field potentials in the NAc in unanesthetized mice [242], suggesting a potential role for activity-dependent synapse strengthening mechanisms.”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [242]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Acute administration of NMDA receptor antagonists produces transient psychosis-like activity in healthy humans and exacerbates the pre-existing symptoms in stabilised schizophrenic individuals (Krystal et al. 1994; Lahti et al. 1995).”
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120 · cited 1×
“Abnormal oscillatory activity recorded in EEG has been associated with schizophrenia (Uhlhaas and Singer 2010; Spencer 2011).”
The brain reward circuitry in mood disorders
Russo, S. J., & Nestler, E. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3381 · Cited by 1,870
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 4×
“NMDA receptor antagonists appear to preferentially block NMDA receptors in cortical interneurons (Homayoun and Moghaddam 2007) and GABAergic neurons of the reticular nucleus of the thalamus (Troyano-Rodriguez et al. 2014).”
InfluentialSubanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921 · cited 1×
“Acute administration of NMDA receptor antagonists produces transient psychosis-like activity in healthy humans and exacerbates the pre-existing symptoms in stabilised schizophrenic individuals (Krystal et al. 1994; Lahti et al. 1995).”
Convergence and segregation of ventral striatal inputs and outputs
GROENEWEGEN, H. J., WRIGHT, C. I., BEIJER, A. V. J., & VOORN, P. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09260.x · Cited by 684 · cited 2×
“cortex, amygdala, hippocampus and thalamus (Groenewegen et al. 1999), and a dense dopaminergic projection from the ventral tegmental area.”
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662 · cited 1×
“Schizophrenia”
Choudhary, M. S., Craigo, S., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592
Gating of information flow within the limbic system and the pathophysiology of schizophrenia
Grace, A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00049-1 · Cited by 519 · cited 1×
“The nucleus accumbens (NAc) is a brain region that has been implicated widely in the pathophysiology of schizophrenia (Grace 2000).”
Celada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323 · cited 2×
“Clozapine and several other atypical antipsychotic drugs possess partial agonistic activity at 5-HT1A receptors (for review, see Celada et al. 2013).”
InfluentialPinault, D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.006 · Cited by 315 · cited 2×
“…Limbic System, Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland 2 The Hull York Medical School, University of York, Heslington, York YO10 5DD, UK Middleton et al. 2008; Roopun et al. 2008; Kocsis 2012) and electrocorticograms (Pinault 2008; Phillips et al. 2012).”
Holmes, A., Wrenn, C. C., Harris, A. P., Thayer, K. E., & Crawley, J. N. (2002) · Genes, Brain and Behavior · doi:10.1046/j.1601-1848.2001.00005.x · Cited by 274 · cited 1×
“Therefore, we also examined HFO in the behaviourally distinct BALB/c strain of mice (Holmes et al. 2002; Sik et al. 2003; Bothe et al. 2005).”
BindingDB (2011) · PubMed · doi:10.7270/q2154fjq · Cited by 224
Depoortère, R., Dargazanli, G., Estenne-Bouhtou, G., Coste, A., Lanneau, C., Desvignes, C., Poncelet, M., Heaulme, M., Santucci, V., Decobert, M., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300772 · Cited by 220
Gleason, S. D., & Shannon, H. E. (1997) · Psychopharmacology · doi:10.1007/s002130050165 · Cited by 216 · cited 4×
“Selection of drugs and doses were based on published findings demonstrating reversal of the effects of NMDA receptor antagonists on motor, cognitive or neurotransmitter effects (Gleason and Shannon 1997; Ninan and Kulkarni 1998; Higgins et al. 2003; Mirjana et al. 2004; Ligneau et al. 2007; Horiguchi et al. 2011; Brab…”
InfluentialPerformance of different mouse strains in an object recognition task
Şık, A., van Nieuwehuyzen, P., Prickaerts, J., & Blokland, A. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00117-7 · Cited by 215 · cited 1×
“Therefore, we also examined HFO in the behaviourally distinct BALB/c strain of mice (Holmes et al. 2002; Sik et al. 2003; Bothe et al. 2005).”
Roth, B. L., Craigo, S. C., Choudhary, M. S., Uluer, A., Monsma, F. J., Shen, Y., Meltzer, H. Y., & Sibley, D. R. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38596-4 · Cited by 214 · cited 2×
“Clozapine possesses antagonist properties at many other receptors, including 5- HT2A (Canton et al. 1994), 5-HT7 (Roth et al. 1994) and H3 receptors (Rodrigues et al. 1995).”
Ketamine Modulates Theta and Gamma Oscillations
Lazarewicz, M. T., Ehrlichman, R. S., Maxwell, C. R., Gandal, M. J., Finkel, L. H., & Siegel, S. J. (2010) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2009.21305 · Cited by 209 · cited 1×
“In freely moving mice, ketamine has been shown to decrease the power of basal hippocampal theta (3–12 Hz) and increase gamma (30–80 Hz) power (Lazarewicz et al. 2010); however, effects on HFO remain largely unknown.”
The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.004 · Cited by 208 · cited 2×
“Glycine is a co-agonist of NMDA receptors which at high doses has been found to have antipsychotic properties in humans (Balu and Coyle 2015).”
Wolf, J. A., Moyer, J. T., Lazarewicz, M. T., Contreras, D., Benoit-Marand, M., O'Donnell, P., & Finkel, L. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2220-05.2005 · Cited by 191 · cited 2×
“NMDA receptors play an important role in the activity of medium spiny neurons, in particular the transition from hyperpolarised ‘down’ states to ‘up’ ready-to-fire states (Vergara et al. 2003; Wolf et al. 2005).”
Higgins, G. A., Enderlin, M., Haman, M., & Fletcher, P. J. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1549-0 · Cited by 179 · cited 4×
“Selection of drugs and doses were based on published findings demonstrating reversal of the effects of NMDA receptor antagonists on motor, cognitive or neurotransmitter effects (Gleason and Shannon 1997; Ninan and Kulkarni 1998; Higgins et al. 2003; Mirjana et al. 2004; Ligneau et al. 2007; Horiguchi et al. 2011; Brab…”
InfluentialNewman‐Tancredi, A., & Kleven, M. S. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2247-y · Cited by 174 · cited 1×
“These observations have led to the development of novel antipsychotic compounds such as aripiprazole and lurasidone (for review, see Newman-Tancredi and Kleven 2011).”
Karasawa, J.-I., Hashimoto, K., & Chaki, S. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.07.033 · Cited by 173 · cited 2×
“…these compounds reduce psychotomimetic-induced hyperlocomotion (Boulay et al. 2008), as well as cognitive deficits induced by NMDA receptor antagonists, including attentional deficits, novel object recognition and latent inhibition (Depoortere et al. 2005; Karasawa et al. 2008; Black et al. 2009).”
Kargieman, L., Santana, N., Mengod, G., Celada, P., & Artigas, F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704848104 · Cited by 168 · cited 2×
“15 mg/kg), close to the concentration reported to reverse effect of phencyclidineinduced increase in cortical pyramidal cell firing (Kargieman et al. 2007), was also without effect on the increases in HFO power or frequency produced by MK801.”
InfluentialRoopun, A. K., Cunningham, M. O., Racca, C., Alter, K., Traub, R. D., & Whittington, M. A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn059 · Cited by 165 · cited 2×
“…Limbic System, Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland 2 The Hull York Medical School, University of York, Heslington, York YO10 5DD, UK Middleton et al. 2008; Roopun et al. 2008; Kocsis 2012) and electrocorticograms (Pinault 2008; Phillips et al. 2012).”
Self-citationKocsis, B. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.002 · Cited by 159 · cited 1×
“…Limbic System, Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland 2 The Hull York Medical School, University of York, Heslington, York YO10 5DD, UK Middleton et al. 2008; Roopun et al. 2008; Kocsis 2012) and electrocorticograms (Pinault 2008; Phillips et al. 2012).”
Baseline gamma power during auditory steady-state stimulation in schizophrenia
M. Spencer, K. (2012) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2011.00190 · Cited by 155 · cited 1×
“Abnormal oscillatory activity recorded in EEG has been associated with schizophrenia (Uhlhaas and Singer 2010; Spencer 2011).”
Hunt, M. J., Raynaud, B., & Garcia, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.020 · Cited by 146 · cited 5×
“oscillation (HFO; 130–180 Hz) recorded in the rat NAc that is enhanced substantially following systemic or local administration of NMDA receptor antagonists (Hunt et al. 2006).”
Self-citationFunctional Properties of Striatal Fast-Spiking Interneurons
Berke, J. D. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00045 · Cited by 140 · cited 1×
“Although the major cell type in the NAc is medium spiny projection neurons, which comprise between 90 and 95 %, several different classes of interneurons are known to be present, including calbindin, parvalbumin, somatostatin and large cholinergic subtypes (Berke 2011; Russo and Nestler 2013).”
Horiguchi, M., Huang, M., & Meltzer, H. Y. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180638 · Cited by 130
Spontaneous Voltage Oscillations in Striatal Projection Neurons in a Rat Corticostriatal Slice
Vergara, R., Rick, C., Hernández‐López, S., Laville, J. A., Guzman, J. N., Galarraga, E., Surmeier, D. J., & Bargas, J. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.050799 · Cited by 127 · cited 2×
“NMDA receptors play an important role in the activity of medium spiny neurons, in particular the transition from hyperpolarised ‘down’ states to ‘up’ ready-to-fire states (Vergara et al. 2003; Wolf et al. 2005).”
Pen, G. L., Kew, J. N. C., Alberati, D., Borroni, E., Heitz, M., & Moreau, J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00374-3 · Cited by 114 · cited 2×
“Glycine has been shown to reverse deficits in pre-pulse inhibition in a rat neonatal ventral hippocampal lesion model (Le Pen et al. 2003).”
InfluentialMiddleton, S., Jalics, J., Kispersky, T., LeBeau, F. E. N., Roopun, A. K., Kopell, N. J., Whittington, M. A., & Cunningham, M. O. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809302105 · Cited by 113 · cited 1×
“…Limbic System, Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland 2 The Hull York Medical School, University of York, Heslington, York YO10 5DD, UK Middleton et al. 2008; Roopun et al. 2008; Kocsis 2012) and electrocorticograms (Pinault 2008; Phillips et al. 2012).”
Self-citationLigneau, X., Landais, L., Perrin, D., Piriou, J., Uguen, M., Denis, E., Robert, P., Parmentier, R., Anaclet, C., Lin, J., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.023 · Cited by 110 · cited 2×
“Selection of drugs and doses were based on published findings demonstrating reversal of the effects of NMDA receptor antagonists on motor, cognitive or neurotransmitter effects (Gleason and Shannon 1997; Ninan and Kulkarni 1998; Higgins et al. 2003; Mirjana et al. 2004; Ligneau et al. 2007; Horiguchi et al. 2011; Brab…”
Behavioral differences among fourteen inbred mouse strains commonly used as disease models.
Bothe, G. W. M., Bolivar, V. J., Vedder, M., & Geistfeld, J. G. (2005) · PubMed · Cited by 106
Mirjana, C., Baviera, M., Invernizzi, R. W., & Balducci, C. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300479 · Cited by 102 · cited 2×
“…subtypes can block NMDA receptor antagonist-induced hyperlocomotion (Gleason and Shannon 1997) and attentional impairments (Higgins et al. 2003; Mirjana et al. 2004) and may reverse dysfunctional glutamatergic transmission produced by NMDA receptor antagonists (Ceglia et al. 2004; McOmish et…”
Phillips, K. G., Cotel, M. C., McCarthy, A. P., Edgar, D. M., Tricklebank, M., O’Neill, M. J., Jones, M. W., & Wafford, K. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.006 · Cited by 100 · cited 3×
“…Limbic System, Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland 2 The Hull York Medical School, University of York, Heslington, York YO10 5DD, UK Middleton et al. 2008; Roopun et al. 2008; Kocsis 2012) and electrocorticograms (Pinault 2008; Phillips et al. 2012).”
InfluentialNikiforuk, A., Kos, T., Fijał, K., Hołuj, M., Rafa, D., & Popik, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066695 · Cited by 99 · cited 3×
“…of studies have demonstrated that a HFO band can be recorded in a variety of neuroanatomical and functionally distinct regions following injection of NMDA receptor antagonist (Hunt et al. 2011; Nicolas et al. 2011; Kulikova et al. 2012; Phillips et al. 2012; Ji et al. 2013; Hiyoshi et al. 2014).”
InfluentialBoulay, D., Pichat, P., Dargazanli, G., Estenne‐Bouhtou, G., Terranova, J.-P., Rogacki, N., Stemmelin, J., COSTE, A., Lanneau, C., Desvignes, C., et al. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.06.009 · Cited by 90 · cited 2×
“In animal models, these compounds reduce psychotomimetic-induced hyperlocomotion (Boulay et al. 2008), as well as cognitive deficits induced by NMDA receptor antagonists, including attentional deficits, novel object recognition and latent inhibition (Depoortere et al. 2005; Karasawa et al. 2008;…”
InfluentialBlack, M. D., Varty, G. B., Arad, M., Barak, S., Levie, A. D., Boulay, D., Pichat, P., Griebel, G., & Weiner, I. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1289-2 · Cited by 89
Ma, J., & Leung, L.-W. S. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00138-8 · Cited by 85 · cited 13×
“4. b LFP expressed as a spectrogram from a representative mouse.”
InfluentialCeglia, I., Carli, M., Baviera, M., Renoldi, G., Calcagno, E., & Invernizzi, R. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02704.x · Cited by 79 · cited 2×
“2004) and may reverse dysfunctional glutamatergic transmission produced by NMDA receptor antagonists (Ceglia et al. 2004; McOmish et al. 2012).”
Ketamine-Induced Oscillations in the Motor Circuit of the Rat Basal Ganglia
Nicolás, M. J., López‐Azcárate, J., Valencia, M., Alegre, M., Pérez-Alcázar, M., Iriarte, J., & Artieda, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021814 · Cited by 74 · cited 2×
“…of studies have demonstrated that a HFO band can be recorded in a variety of neuroanatomical and functionally distinct regions following injection of NMDA receptor antagonist (Hunt et al. 2011; Nicolas et al. 2011; Kulikova et al. 2012; Phillips et al. 2012; Ji et al. 2013; Hiyoshi et al. 2014).”
InfluentialHiyoshi, T., Kambe, D., Karasawa, J.-I., & Chaki, S. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.037 · Cited by 72 · cited 2×
“…of studies have demonstrated that a HFO band can be recorded in a variety of neuroanatomical and functionally distinct regions following injection of NMDA receptor antagonist (Hunt et al. 2011; Nicolas et al. 2011; Kulikova et al. 2012; Phillips et al. 2012; Ji et al. 2013; Hiyoshi et al. 2014).”
InfluentialKulikova, S. P., Tolmacheva, E. A., Anderson, P., Gaudias, J., Adams, B. E. L., Zheng, T. W., & Pinault, D. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08263.x · Cited by 70 · cited 2×
“…of studies have demonstrated that a HFO band can be recorded in a variety of neuroanatomical and functionally distinct regions following injection of NMDA receptor antagonist (Hunt et al. 2011; Nicolas et al. 2011; Kulikova et al. 2012; Phillips et al. 2012; Ji et al. 2013; Hiyoshi et al. 2014).”
InfluentialClozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain
McOmish, C. E., Lira, A., Hanks, J. B., & Gingrich, J. A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.139 · Cited by 69 · cited 2×
“2004) and may reverse dysfunctional glutamatergic transmission produced by NMDA receptor antagonists (Ceglia et al. 2004; McOmish et al. 2012).”
Hunt, M. J., Falinska, M., Łęski, S., Wójcik, D. K., & Kasicki, S. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110362126 · Cited by 69 · cited 6×
“Differences were considered significant when p<0.05.”
Self-citationBradford, A. M., Savage, K. M., Jones, D. N. C., & Kalinichev, M. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1938-0 · Cited by 62
Wittmann, M., Marino, M. J., Henze, D. A., Seabrook, G. R., & Conn, P. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080200 · Cited by 62 · cited 5×
“Additionally, using whole patch cell recordings, it has been shown that bath application of clozapine, but not haloperidol or the 5-HT2A antagonist MDL100907, potentiates NMDA receptor currents in NAc neurons (Wittmann et al. 2005).”
Influential5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion
Ninan, I., & Kulkarni, S. K. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00591-3 · Cited by 59 · cited 4×
“…demonstrating reversal of the effects of NMDA receptor antagonists on motor, cognitive or neurotransmitter effects (Gleason and Shannon 1997; Ninan and Kulkarni 1998; Higgins et al. 2003; Mirjana et al. 2004; Ligneau et al. 2007; Horiguchi et al. 2011; Brabant et al. 2013; Nikiforuk et al.…”
InfluentialGlycine and D-serine decrease MK-801-induced hyperactivity in mice
Nilsson, M. K. L., Carlsson, A., & Carlsson, M. L. (1997) · Journal of Neural Transmission · doi:10.1007/bf01294720 · Cited by 55 · cited 2×
“4c. Consistent with the findings of others (Nilsson et al. 1997), glycine also reduced MK801enhanced locomotion with respect to saline (p=0.026, paired t test; Fig.”
InfluentialThe histamine H3-receptor inverse agonist Pitolisant improves fear memory in mice
Brabant, C., Charlier, Y., & Tirelli, E. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.063 · Cited by 51 · cited 2×
“Selection of drugs and doses were based on published findings demonstrating reversal of the effects of NMDA receptor antagonists on motor, cognitive or neurotransmitter effects (Gleason and Shannon 1997; Ninan and Kulkarni 1998; Higgins et al. 2003; Mirjana et al. 2004; Ligneau et al. 2007; Horiguchi et al. 2011; Brab…”
Troyano‐Rodriguez, E., Lladó-Pelfort, L., Santana, N., Teruel‐Martí, V., Celada, P., & Artigas, F. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.019 · Cited by 47 · cited 1×
“NMDA receptor antagonists appear to preferentially block NMDA receptors in cortical interneurons (Homayoun and Moghaddam 2007) and GABAergic neurons of the reticular nucleus of the thalamus (Troyano-Rodriguez et al. 2014).”
Interaction of clozapine with the histamine H3 receptor in rat brain
Rodrigues, A. A., Jansen, F. P., Leurs, R., Timmerman, H., & Prell, G. D. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb14934.x · Cited by 41 · cited 3×
“Clozapine possesses antagonist properties at many other receptors, including 5- HT2A (Canton et al. 1994), 5-HT7 (Roth et al. 1994) and H3 receptors (Rodrigues et al. 1995).”
Canton, H., Verrièle, L., & Millan, M. J. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90561-4 · Cited by 41 · cited 8×
“Additionally, using whole patch cell recordings, it has been shown that bath application of clozapine, but not haloperidol or the 5-HT2A antagonist MDL100907, potentiates NMDA receptor currents in NAc neurons (Wittmann et al. 2005).”
InfluentialOlszewski, M., Dolowa, W., Matulewicz, P., Kasicki, S., & Hunt, M. J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.012 · Cited by 39 · cited 11×
“Differences were considered significant when p<0.05.”
Self-citationOlszewski, M., Piasecka, J., Goda, S. A., Kasicki, S., & Hunt, M. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001034 · Cited by 37 · cited 12×
“Differences were considered significant when p<0.05.”
Self-citationLocal injection of MK801 modifies oscillatory activity in the nucleus accumbens in awake rats
Hunt, M. J., Falińska, M., & Kasicki, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102539 · Cited by 36 · cited 2×
“the NAc, increases in the power of HFO produced by NMDA receptor antagonists predominate well above changes found in other frequency bands (Hunt et al. 2010).”
Self-citationKonradsson‐Geuken, Å., Marcus, M. M., Hertel, P., Svensson, T. H., & Jardemark, K. E. (2006) · Synapse · doi:10.1002/syn.20286 · Cited by 34 · cited 1×
“Both clozapine and risperidone potentiate NMDA receptor neurotransmission in cortical neurons (Konradsson et al. 2006).”
Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia
Ji, B., Wang, X., Pinto‐Duarte, A., Kim, M., Caldwell, S., Young, J. W., Behrens, M. M., B, T. J. S. A., Geyer, M. A., & Zhou, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066327 · Cited by 26 · cited 3×
“…of studies have demonstrated that a HFO band can be recorded in a variety of neuroanatomical and functionally distinct regions following injection of NMDA receptor antagonist (Hunt et al. 2011; Nicolas et al. 2011; Kulikova et al. 2012; Phillips et al. 2012; Ji et al. 2013; Hiyoshi et al. 2014).”
InfluentialHistamine H3-Receptor Inverse Agonists as Novel Antipsychotics
Ito, C. (2009) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152409788452036 · Cited by 21 · cited 1×
“Experimental compounds that interact at these sites have been proposed as novel antipsychotics or adjunctive therapy in the treatment of schizophrenia (Wittmann et al. 2005; Ito 2009).”
Cited by
Sapkota, K., Mao, Z., Synowicki, P., Lieber, D., Liu, M., Ikezu, T., Gautam, V., & Monaghan, D. T. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230391 · Cited by 70
“, 2013) and glycine (Hunt et al., 2015) were found to reduce the peak frequency of NMDAR antagonist-induced HFOs.”
Montani, C., Canella, C., Schwarz, A. J., Li, J., Gilmour, G., Galbusera, A., Wafford, K. A., Gutierrez‐Barragan, D., McCarthy, A. P., Shaw, D. B., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00916-0 · Cited by 59
“NMDAR antagonist evoked increases in HFO activity in nucleus accumbens have previously be shown to be reduced by clozapine [68].”
BackgroundIn vivo electrophysiological recordings of the effects of antidepressant drugs
Fitzgerald, P. J., & Watson, B. O. (2019) · Experimental Brain Research · doi:10.1007/s00221-019-05556-5 · Cited by 54
Plasticity of synapses and reward circuit function in the genesis and treatment of depression
Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01422-1 · Cited by 40
“Like the effects of ketamine in the cortex, ketamine increases the power of high-frequency oscillations of local field potentials in the NAc in unanesthetized mice [242], suggesting a potential role for activity-dependent synapse strengthening mechanisms.”
BackgroundPetersson, P., Halje, P., & Cenci, M. A. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181480 · Cited by 34
“that psychotomimetic drugs known to act on differ580 ent receptor systems—for example on either 5-HT2A 581 or NMDA receptors have been found to induce very 582 similar HFO activity in animals [26, 84].”
BackgroundMethod
Metadata
- Authors
- Hunt, M. J., Olszewski, M., Piasecka, J., Whittington, M. A., & Kasicki, S.
- Affiliations
- Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL)
- University of York (GB)
- Corresponding author
- Hunt, Mark J.
- Venue
- Psychopharmacology
- Published
- 2015-10-08
- Volume
- 232
- Issue
- 24
- Pages
- 4525-4535
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC4646921
- OpenAlex
- W1956040624
- Cited by
- 20
- References
- 61
- Citations by year
- 2025: 2 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 1
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (098352/Z/12/Z, 098352)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- NMDA receptor antagonists, antipsychotic drugs, high-frequency oscillations, nucleus accumbens, ketamine, MK-801, clozapine, haloperidol, 5-HT1A receptor, NMDA receptor glycine site, schizophrenia, local field potentials, freely moving mice
- MeSH terms
- Animals, Clozapine, Dose-Response Relationship, Drug, Haloperidol, Ketamine, Male, Nucleus Accumbens, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Dizocilpine Maleate, Rats, Wistar, Excitatory Amino Acid Antagonists, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.